137 Stock Overview
A biotechnology company, develops and commercializes medicines for immune-mediated diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Aldeyra Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.70 |
| 52 Week High | US$5.79 |
| 52 Week Low | US$2.32 |
| Beta | 1.43 |
| 11 Month Change | -4.24% |
| 3 Month Change | -2.53% |
| 1 Year Change | 102.76% |
| 33 Year Change | -29.32% |
| 5 Year Change | -34.72% |
| Change since IPO | -5.09% |
Recent News & Updates
Recent updates
Shareholder Returns
| 137 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 17.5% | -0.7% | 0.2% |
| 1Y | 102.8% | -17.2% | 8.5% |
Return vs Industry: 137 exceeded the German Biotechs industry which returned -17.2% over the past year.
Return vs Market: 137 exceeded the German Market which returned 8.5% over the past year.
Price Volatility
| 137 volatility | |
|---|---|
| 137 Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 6.5% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.9% |
| 10% least volatile stocks in DE Market | 2.3% |
Stable Share Price: 137's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 137's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9 | Todd Brady | www.aldeyra.com |
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases. The company also develops ADX-629, an orally administered RASP modulator for treatment of COVID-19, atopic asthma, psoriasis, and alcohol intoxication; and ADX-2191, a dihydrofolate reductase inhibitor for the treatment retinitis pigmentosa, as well as rare retinal diseases characterized by inflammation and vision loss.
Aldeyra Therapeutics, Inc. Fundamentals Summary
| 137 fundamental statistics | |
|---|---|
| Market cap | €277.35m |
| Earnings (TTM) | -€43.02m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-6.4x
P/E RatioIs 137 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 137 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$44.80m |
| Earnings | -US$44.80m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.75 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 18.0% |
How did 137 perform over the long term?
See historical performance and comparison